Pharma marketing & medical communications IndiaSoutheast AsiaMiddle EastAfrica

Medical Affairs: Outsourcing and Partnerships

Outsourced Medical Affairs: Models and What to Expect

What pharma companies outsource in medical affairs, the three working models, the first 90 days and the questions to ask a partner.

A medical affairs team reviewing work together at a table
Fig 1. A medical affairs team and its partner agree who reviews what before the first deliverable.

Medical affairs teams are asked for more every year: more evidence, more HCP education, more scientific content across more channels. Few can hire fast enough for a launch peak or a new market. Outsourcing part of the work to a specialist partner is how many pharma companies close the gap without losing medical control.

1. What Companies Outsource, and What They Keep

WorkUsually outsourced?What stays with the company
Medical writing and publicationsOftenAuthorship decisions and final approval
Medical information and HCP queriesOftenEscalations and pharmacovigilance ownership
Advisory boards and KOL programmesOftenThe relationships with each KOL
Medical education and CMEOftenChoice of topics and faculty
Real-world evidence studiesOften, with research partnersStudy questions and data ownership
Field medical (MSL) teamsSometimes, as contract MSLsTerritory strategy and insight review
Medical governance and sign-offNeverAll of it

The rule of thumb: a partner can do the work, but the company keeps the medical judgement, the final sign-off and its relationships with HCPs.

2. Three Working Models

Project support. One defined deliverable: an advisory board, a consensus paper, a CME series. It suits teams that have the strategy but not the hands.

Embedded team. Medical writers, programme managers or contract MSLs who work inside the client's processes for 6 to 12 months. It suits launch peaks and gaps while hiring.

Outsourced function. The partner runs medical affairs activity for a product or market under the client's governance. It suits market entry, or a product too small for its own team.

3. The First 90 Days

  1. Align on SOPs: whose standard operating procedures apply, and where they differ.
  2. Train the partner team on the product, the label and the company's compliance rules, including UCPMP 2024.
  3. Set governance: who reviews what, meeting rhythm, and how issues are escalated.
  4. Set up pharmacovigilance: how adverse events reported to the partner reach the safety team within the required time.
  5. Agree the first deliverables and the measures of quality, not only of volume.

4. Questions to Ask a Partner

  • Who are the medical writers and reviewers, and what are their qualifications?
  • How does a piece of content move from draft to medical approval?
  • How do you keep medical programmes separate from promotion?
  • Which therapy areas have you worked in, and can we see examples?
  • How do you handle adverse events and HCP data?
  • What happens to the work and the knowledge when the contract ends?

5. Risks to Manage

Three risks need a plan from day one. HCPs should stay in a relationship with the company, not only with the partner. The line between medical and promotional work must stay clear in governance, not just on paper. And every deliverable should be documented so that knowledge stays with the company.

OneAlphaMed provides medical affairs services as project support, embedded teams or a full function. Examples on the site include a 15-country Delphi consensus and an asynchronous oncology advisory board. For how the function is changing, read the role of medical affairs in 2026.

Share on: